News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
862,611 Results
Type
Article (87526)
Company Profile (807)
Press Release (774256)
Multimedia
Podcasts (177)
Webinars (28)
Section
Business (233091)
Career Advice (4140)
Deals (39809)
Drug Delivery (140)
Drug Development (91280)
Employer Resources (203)
FDA (18297)
Job Trends (17407)
News (397482)
Policy (39929)
Tag
Academia (3005)
Academic (2)
Accelerated approval (18)
Adcomms (35)
Allergies (129)
Alliances (56980)
ALS (147)
Alzheimer's disease (1690)
Antibody-drug conjugate (ADC) (263)
Approvals (18333)
Artificial intelligence (514)
Autoimmune disease (102)
Automation (30)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (167)
Biotechnology (485)
Bladder cancer (139)
Brain cancer (53)
Breast cancer (521)
Cancer (4144)
Cardiovascular disease (360)
Career advice (3562)
Career pathing (38)
CAR-T (256)
CDC (57)
Cell therapy (709)
Cervical cancer (33)
Clinical research (75789)
Collaboration (1441)
Company closure (4)
Compensation (956)
Complete response letters (62)
COVID-19 (2962)
CRISPR (85)
C-suite (622)
Cystic fibrosis (141)
Data (4886)
Decentralized trials (2)
Denatured (64)
Depression (113)
Diabetes (462)
Diagnostics (7103)
Digital health (37)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (244)
Drug pricing (195)
Drug shortages (36)
Duchenne muscular dystrophy (209)
Earnings (99142)
Editorial (55)
Employer branding (25)
Employer resources (172)
Events (133440)
Executive appointments (998)
FDA (20880)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (16)
Funding (1298)
Gene editing (180)
Generative AI (52)
Gene therapy (565)
GLP-1 (1033)
Government (5392)
Grass and pollen (8)
Guidances (372)
Healthcare (20939)
HIV (49)
Huntington's disease (41)
IgA nephropathy (66)
Immunology and inflammation (256)
Immuno-oncology (22)
Indications (59)
Infectious disease (3212)
Inflammatory bowel disease (191)
Inflation Reduction Act (16)
Influenza (102)
Intellectual property (198)
Interviews (816)
IPO (17931)
IRA (59)
Job creations (5197)
Job search strategy (2866)
Kidney cancer (17)
Labor market (81)
Layoffs (643)
Leadership (37)
Legal (10150)
Liver cancer (92)
Longevity (13)
Lung cancer (592)
Lymphoma (285)
Machine learning (33)
Management (66)
Manufacturing (672)
MASH (146)
Medical device (14909)
Medtech (14935)
Mergers & acquisitions (22777)
Metabolic disorders (1182)
Multiple sclerosis (141)
NASH (23)
Neurodegenerative disease (237)
Neuropsychiatric disorders (63)
Neuroscience (2761)
NextGen: Class of 2025 (7687)
Non-profit (5098)
Now hiring (60)
Obesity (569)
Opinion (316)
Ovarian cancer (140)
Pain (172)
Pancreatic cancer (177)
Parkinson's disease (245)
Partnered (32)
Patents (429)
Patient recruitment (337)
Peanut (57)
People (66358)
Pharmaceutical (145)
Pharmacy benefit managers (29)
Phase I (23379)
Phase II (32885)
Phase III (24802)
Pipeline (2850)
Policy (302)
Postmarket research (3554)
Preclinical (10551)
Press Release (72)
Prostate cancer (204)
Psychedelics (52)
Radiopharmaceuticals (282)
Rare diseases (708)
Real estate (7422)
Recruiting (79)
Regulatory (28132)
Reports (65)
Research institute (2695)
Resumes & cover letters (651)
Rett syndrome (16)
RNA editing (15)
RSV (76)
Schizophrenia (140)
Series A (213)
Series B (160)
Service/supplier (30)
Sickle cell disease (85)
Special edition (26)
Spinal muscular atrophy (170)
Sponsored (42)
Startups (4319)
State (2)
Stomach cancer (17)
Supply chain (103)
Tariffs (96)
The Weekly (111)
Vaccines (1062)
Venture capital (68)
Weight loss (403)
Women's health (60)
Worklife (21)
Date
Today (306)
Last 7 days (865)
Last 30 days (3102)
Last 365 days (33645)
2025 (28147)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1283)
Alabama (81)
Alaska (7)
Arizona (309)
Arkansas (14)
Asia (51068)
Australia (8979)
California (9824)
Canada (2929)
China (944)
Colorado (414)
Connecticut (436)
Delaware (283)
Europe (117365)
Florida (1445)
Georgia (324)
Hawaii (3)
Idaho (67)
Illinois (827)
India (55)
Indiana (482)
Iowa (20)
Japan (338)
Kansas (127)
Kentucky (39)
Louisiana (22)
Maine (78)
Maryland (1313)
Massachusetts (7364)
Michigan (318)
Minnesota (584)
Mississippi (4)
Missouri (124)
Montana (33)
Nebraska (26)
Nevada (109)
New Hampshire (80)
New Jersey (2726)
New Mexico (32)
New York (2653)
North Carolina (1436)
North Dakota (10)
Northern California (4505)
Ohio (309)
Oklahoma (22)
Oregon (51)
Pennsylvania (2032)
Puerto Rico (20)
Rhode Island (46)
South America (1655)
South Carolina (51)
South Dakota (1)
Southern California (3749)
Tennessee (153)
Texas (1541)
United States (36152)
Utah (297)
Virginia (254)
Washington D.C. (84)
Washington State (838)
West Virginia (4)
Wisconsin (101)
Wyoming (2)
There are 862,611 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Vertex’s New Products Dim as Analysts Eye Kidney Portfolio
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy.
November 4, 2025
·
5 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Sarepta’s DMD Exon-Skippers Fail Confirmatory Study, Stock Craters
Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging trends” in efficacy.
November 4, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
UCB Wins First FDA Approval for Ultra-Rare Mitochondrial Disease
Kygevvi is indicated for patients with thymidine kinase 2 deficiency whose symptoms arise by 12 years of age. The disease manifests as muscle weakness and can become life-threatening in severe instances.
November 4, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Secura Bio Announces Poster Presentation Highlighting Extended Follow Up Analyses from Phase 2 PRIMO Trial at the 2025 American Society of Hematology Meeting
November 4, 2025
·
5 min read
Press Releases
Purespring to present three posters at the American Society of Nephrology Kidney Week 2025
November 4, 2025
·
5 min read
Press Releases
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
November 4, 2025
·
11 min read
Press Releases
EDAP to Present at Jefferies Global Healthcare Conference 2025 in London
November 4, 2025
·
1 min read
Press Releases
Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
November 4, 2025
·
6 min read
Press Releases
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
November 4, 2025
·
7 min read
Press Releases
Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
November 4, 2025
·
5 min read
1 of 86,262
Next
